Clinical Trial Updates11 May 2026
Entrada shares dive as Duchenne results disappoint
Entrada Therapeutics reported early data from its Phase 1/2 study for ENTR-601-44, an experimental Duchenne muscular dystrophy treatment. While the company...
Clinical Trial Insights
Clinical Trial Updates
Clinical Trial Updates11 May 2026
Assembly Biosciences Reports First Quarter 2026 Financial Results and Recent Highlights
Assembly Biosciences reported its first quarter 2026 financial results and recent operational highlights. The company completed Phase 1b studies for ABI-5366...
Clinical Trial Updates11 May 2026
LeonaBio Reports First Quarter 2026 Financial Results and Provides Business Update
LeonaBio, Inc. reported its first-quarter 2026 financial results and provided key business updates, primarily focusing on the advancement of its lead programs....
Clinical Trial Updates07 May 2026
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
Cellectar Biosciences announced positive 12-month follow-up data from its Phase 2b CLOVER WaM clinical trial evaluating iopofosine I 131 in 55 patients with...
Clinical Trial Updates07 May 2026
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer
Zentalis Pharmaceuticals has dosed the first patient in its Phase 3 ASPENOVA clinical trial (NCT07546500) evaluating azenosertib for Cyclin E1-positive...
Clinical Trial Updates07 May 2026
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
Nuvectis Pharma reported its first-quarter 2026 financial results and provided an update on its NXP900 clinical program. The company is actively enrolling...
Clinical Trial Updates07 May 2026
Sarepta, Amylyx and Neumora look ahead to key catalysts as Q1 earnings roll in
Sarepta Therapeutics is navigating significant challenges, including patient deaths linked to its gene therapy Elevidys, but is poised for several key...
Clinical Trial Updates07 May 2026
Viridian Data Lift Prospects for Thyroid Eye Disease Drug
Viridian Therapeutics announced positive late-stage data for its subcutaneous drug, elegrobart, in patients with chronic thyroid eye disease. The trial...
Clinical Trial Updates07 May 2026
QurAlis’ Phase 2 data bolster case for genetic approach to sporadic ALS
QurAlis presented interim Phase 2 data for its antisense oligonucleotide (ASO), QRL-201, in 69 patients with amyotrophic lateral sclerosis (ALS) at Target...
Clinical Trial Updates07 May 2026
Calluna Pharma Completes Enrollment in Phase II AURORA Study for Idiopathic Pulmonary Fibrosis
The idiopathic pulmonary fibrosis (IPF) market is gaining significant attention, projected to grow from nearly $3 billion in 2025 to $7 billion by 2035, driven...
Clinical Trial Updates07 May 2026
Cytokinetics Heart Drug Scores in Closely Watched Trial
Cytokinetics announced positive Phase 3 trial results for its drug Myqorzo in people with non-obstructive hypertrophic cardiomyopathy (HCM). The drug met its...
Clinical Trial Updates05 May 2026
Summit shares descend as PD-1/VEGF asset misses early survival mark
Summit Therapeutics' shares dropped significantly after its anti-PD-1/VEGF bispecific antibody, ivonescimab, failed to meet an early interim progression-free...
Clinical Trial Updates05 May 2026
Celcuity strengthens case for ASCO-spotlighted breast cancer drug
Celcuity announced positive results from a Phase 3 trial for its experimental breast cancer drug, gedatolisib, demonstrating that two- and three-drug...
Clinical Trial Updates01 May 2026
Confo Therapeutics Announces Phase 2 Clinical Trial Initiation by Lilly for Peripheral Pain Candidate, CFTX-1554
Confo Therapeutics announced the initiation of a Phase 2a clinical trial for CFTX-1554, its novel angiotensin II type 2 receptor (AT2R) antagonist for...
Clinical Trial Updates01 May 2026
BMS Positions Cobenfy as Safer Alternative Ahead of Pivotal Alzheimer’s Psychosis Readout
Bristol Myers Squibb is positioning its schizophrenia drug, Cobenfy, as a potentially safer alternative for Alzheimer's disease psychosis, an indication...
Clinical Trial Updates01 May 2026
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
Phathom Pharmaceuticals reported strong financial results for Q1 2026, with net revenues more than doubling year-over-year to $58.3 million, driven by the...
Clinical Trial Updates01 May 2026
Syndax Reports First Quarter 2026 Financial Results and Provides Business Update
Syndax Pharmaceuticals reported strong financial results for Q1 2026, with total revenue reaching $64.9 million, a 224% year-over-year increase. Revuforj net...
Clinical Trial Updates01 May 2026
Lilly CEO shades amylin rivals AbbVie, Pfizer in cutthroat battle for obesity’s next act
Eli Lilly CEO David Ricks has positioned the company's investigational obesity drug, eloralintide, as superior to rival amylin assets from companies like...
Clinical Trial Updates01 May 2026
GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints
Alector and GSK have discontinued their Phase 2 PROGRESS-AD trial for nivisnebart in early-stage Alzheimer’s disease due to a lack of significant efficacy. An...
Clinical Trial Updates30 Apr 2026
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
Zealand Pharma and Roche announced their decision to advance petrelintide, a once-weekly amylin analog, into Phase 3 trials for chronic weight management. This...
Clinical Trial Updates30 Apr 2026
GSK’s Shingrix strategy shift drives sales beat even as vaccines slow
GSK reported robust first-quarter 2026 earnings, with total sales increasing 5% year-on-year to £7.6 billion ($10.27 billion). The shingles vaccine Shingrix...
Clinical Trial Updates30 Apr 2026
AstraZeneca bullish on $80B sales goal after beating expectations, Phase 3 data wins
AstraZeneca reported strong first-quarter 2026 sales of $15.3 billion, surpassing analyst expectations of $14.7 billion, driven by 8% constant exchange rate...
Clinical Trial Updates30 Apr 2026
Tonix Pharmaceuticals Presents Phase 1 Data and Plans for Adaptive Phase 2 Study of TNX-4800 for Lyme Disease Prevention
Tonix Pharmaceuticals announced the presentation of Phase 1 data for TNX-4800, a long-acting human monoclonal antibody for Lyme disease prevention, and...
Clinical Trial Updates30 Apr 2026
Imviva Biotech to Present Clinical Data from Ongoing Phase 1/2 Study of CTA313 at the American Society of Gene & Cell Therapy's Annual Meeting
Imviva Biotech announced it will present clinical data from its ongoing open-label Phase 1/2 study of CTA313, a CD19/BCMA dual-targeted allogeneic CAR-T cell...
Clinical Trial Updates30 Apr 2026
Novartis, PTC push Huntington’s drug into Phase 3, mum on accelerated approval
Novartis and PTC Therapeutics are advancing their Huntington's disease candidate, votoplam, into a Phase 3 trial (INVEST-HD) following encouraging interim data...
Clinical Trial Updates29 Apr 2026
Boehringer dual-acting obesity shot hits mark in Phase 3 trial
Boehringer Ingelheim announced positive Phase 3 results for its dual-acting obesity therapy, survodutide, licensed from Zealand Pharma. In the Synchronize-1...
Clinical Trial Updates29 Apr 2026
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
Idorsia Ltd announced strong financial results for Q1 2026, driven by a 74% year-on-year increase in QUVIVIQ net sales to CHF 44 million. The company also...
Clinical Trial Updates29 Apr 2026
Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio
Jyong Biotech Ltd. announced advancements in market access strategies for its innovative plant-based drugs, Botreso and PCP, following an analysis of their...
Clinical Trial Updates29 Apr 2026
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
Kiniksa Pharmaceuticals reported strong financial results for the first quarter of 2026, driven by significant growth in ARCALYST net product revenue, which...
Clinical Trial Updates28 Apr 2026
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
Eton Pharmaceuticals has initiated a pilot clinical study for ET-700, an extended-release zinc acetate formulation under development for Wilson disease. The...
Clinical Trial Updates28 Apr 2026
Biomea Fusion Announces Positive 52-Week Results from Phase 2 COVALENT-112 Trial in Type 1 Diabetes Showing C-Peptide Improvement and Durability Following 12-Weeks of Icovamenib Treatment
Biomea Fusion announced positive 52-week results from its Phase 2 COVALENT-112 trial of icovamenib in type 1 diabetes (T1D). In patients diagnosed within 0-3...
Clinical Trial Updates28 Apr 2026
Compass shares crash as ‘confounding’ survival data raise approvability questions for bispecific
Compass Therapeutics' bispecific drug, tovecimig, met its primary endpoint of progression-free survival (PFS) in the Phase 2/3 COMPANION-002 study for biliary...
Clinical Trial Updates28 Apr 2026
Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis
Sionna Therapeutics has completed enrollment for its PreciSION CF Phase 2a proof-of-concept trial. This study evaluates SION-719, a first-in-class nucleotide...
Clinical Trial Updates28 Apr 2026
Oruka Surges as Long-Acting Psoriasis Drug Shows Early Promise
Oruka Therapeutics' experimental drug ORKA-001 demonstrated strong efficacy in a Phase 2 trial for plaque psoriasis, achieving total skin clearance (PASI 100)...
Clinical Trial Updates27 Apr 2026
Pfizer Culls Early PD-L1 Asset After Series of Clinical Wins, Deals in Cancer
Pfizer has discontinued its early-stage PD-L1 program, PF-08046037, which was being evaluated in a Phase 1 study for a variety of advanced or metastatic...
Clinical Trial Updates24 Apr 2026
Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’
Roche is defending its amylin analog petrelintide for obesity, despite its Phase 2 ZUPREME-1 study showing a 9% placebo-controlled weight reduction at 42...
Clinical Trial Updates24 Apr 2026
J&J's Imaavy Shows Sustained Benefit in Myasthenia Gravis Over Two Years
Johnson & Johnson's FcRn blocker, Imaavy, demonstrated sustained efficacy in patients with generalized myasthenia gravis (gMG) over two years of follow-up,...
Clinical Trial Updates24 Apr 2026
IMAAVY (nipocalimab) Shows Over Two Years of Sustained Disease Control in Generalised Myasthenia Gravis
Johnson & Johnson announced new long-term data from the Phase 3 Vivacity-MG3 study and its open-label extension (OLE) for nipocalimab (IMAAVY®) in...
Clinical Trial Updates24 Apr 2026
LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer
LeonaBio, Inc. announced it will host a virtual Key Opinion Leader (KOL) event on Wednesday, April 29, 2026, to discuss the evolving treatment landscape for...
Clinical Trial Updates23 Apr 2026
Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial
Moderna has initiated a Phase 3 clinical trial for its mRNA-1018 bird flu vaccine, despite facing a significant loss of U.S. government funding. The trial aims...